JP2017039771A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017039771A5 JP2017039771A5 JP2016212111A JP2016212111A JP2017039771A5 JP 2017039771 A5 JP2017039771 A5 JP 2017039771A5 JP 2016212111 A JP2016212111 A JP 2016212111A JP 2016212111 A JP2016212111 A JP 2016212111A JP 2017039771 A5 JP2017039771 A5 JP 2017039771A5
- Authority
- JP
- Japan
- Prior art keywords
- rankl
- pharmaceutical composition
- breast cancer
- cancer
- rank
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10178346A EP2433644A1 (en) | 2010-09-22 | 2010-09-22 | Breast cancer therapeutics |
| EP10178346.2 | 2010-09-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013529652A Division JP6133778B2 (ja) | 2010-09-22 | 2011-09-22 | 乳癌治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017039771A JP2017039771A (ja) | 2017-02-23 |
| JP2017039771A5 true JP2017039771A5 (enExample) | 2017-08-10 |
Family
ID=43498569
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013529652A Expired - Fee Related JP6133778B2 (ja) | 2010-09-22 | 2011-09-22 | 乳癌治療剤 |
| JP2016212111A Pending JP2017039771A (ja) | 2010-09-22 | 2016-10-28 | 乳癌治療剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013529652A Expired - Fee Related JP6133778B2 (ja) | 2010-09-22 | 2011-09-22 | 乳癌治療剤 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10143747B2 (enExample) |
| EP (2) | EP2433644A1 (enExample) |
| JP (2) | JP6133778B2 (enExample) |
| KR (1) | KR20130118870A (enExample) |
| CN (1) | CN103384530A (enExample) |
| AU (1) | AU2011306917B2 (enExample) |
| BR (1) | BR112013006673A2 (enExample) |
| CA (1) | CA2811556A1 (enExample) |
| CL (1) | CL2013000801A1 (enExample) |
| IL (1) | IL225442A0 (enExample) |
| MX (1) | MX2013003076A (enExample) |
| NZ (1) | NZ608207A (enExample) |
| PH (1) | PH12013500543A1 (enExample) |
| RU (1) | RU2013118325A (enExample) |
| WO (1) | WO2012038504A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2433644A1 (en) | 2010-09-22 | 2012-03-28 | IMBA-Institut für Molekulare Biotechnologie GmbH | Breast cancer therapeutics |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US20190218302A1 (en) * | 2016-05-19 | 2019-07-18 | Probiocon Gmbh | Anti-cancer combination treatment |
| HRP20240167T1 (hr) | 2017-04-28 | 2024-04-26 | Amgen Inc. | Formulacije ljudskih anti-rankl protutijela i postupci njihove upotrebe |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| PT951551E (pt) | 1996-12-23 | 2008-10-28 | Immunex Corp | Ligando para receptor activador de nf-kb, ligando membro da superfamília de tnf |
| WO1998046644A1 (fr) | 1997-04-15 | 1998-10-22 | Snow Brand Milk Products Co., Ltd. | Nouvelle proteine et methode de production associee |
| US5843678A (en) | 1997-04-16 | 1998-12-01 | Amgen Inc. | Osteoprotegerin binding proteins |
| SI0975754T2 (sl) | 1997-04-16 | 2016-04-29 | Amgen Inc., | Vezivni proteini in receptorji osteoprotegerina |
| CA2229449A1 (en) | 1997-04-25 | 1998-10-25 | Takeda Chemical Industries, Ltd. | Novel receptor protein and its use |
| WO1998054201A1 (en) | 1997-05-29 | 1998-12-03 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like protein 8 |
| US6790823B1 (en) * | 1998-04-23 | 2004-09-14 | Amgen Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| US6638727B1 (en) | 1999-01-26 | 2003-10-28 | Cytyc Health Corporation | Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| DE10160151A1 (de) | 2001-01-09 | 2003-06-26 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| WO2001068836A2 (en) | 2000-03-16 | 2001-09-20 | Genetica, Inc. | Methods and compositions for rna interference |
| US20020173478A1 (en) | 2000-11-14 | 2002-11-21 | The Trustees Of The University Of Pennsylvania | Post-transcriptional gene silencing by RNAi in mammalian cells |
| US20040167072A1 (en) | 2001-05-11 | 2004-08-26 | Aggarwal Bharat B. | Inhibitors of receptor activator of NF-kappaB and uses thereof |
| EP1432438A2 (en) * | 2001-06-06 | 2004-06-30 | Immunex Corporation | Use of rank antagonists to treat cancer |
| AU2003207708A1 (en) | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
| US7700574B2 (en) | 2003-09-17 | 2010-04-20 | Isis Pharmaceuticals, Inc. | Modulation of RANKL expression |
| WO2005060627A2 (en) | 2003-12-10 | 2005-07-07 | Auxeris Therapeutics, Inc. | Methods of assessing the risk of non-traumatic bone fracture |
| US20080107597A1 (en) | 2006-01-12 | 2008-05-08 | Anaptys Biosciences, Inc. | Isolation of antibodies that cross-react and neutralize rankl originating from multiple species |
| EP1854458A1 (en) | 2006-05-08 | 2007-11-14 | IMBA-Institut für Molekulare Biotechnologie GmbH | Use of a compound with RANKL activity |
| TW201019959A (en) | 2008-08-19 | 2010-06-01 | Regeneron Pharma | Human antibodies to human RANKL |
| EP2433644A1 (en) | 2010-09-22 | 2012-03-28 | IMBA-Institut für Molekulare Biotechnologie GmbH | Breast cancer therapeutics |
-
2010
- 2010-09-22 EP EP10178346A patent/EP2433644A1/en not_active Withdrawn
-
2011
- 2011-09-22 CN CN2011800544541A patent/CN103384530A/zh active Pending
- 2011-09-22 BR BR112013006673A patent/BR112013006673A2/pt not_active IP Right Cessation
- 2011-09-22 PH PH1/2013/500543A patent/PH12013500543A1/en unknown
- 2011-09-22 KR KR1020137009817A patent/KR20130118870A/ko not_active Ceased
- 2011-09-22 MX MX2013003076A patent/MX2013003076A/es unknown
- 2011-09-22 EP EP11758242.9A patent/EP2618833B1/en not_active Revoked
- 2011-09-22 RU RU2013118325/15A patent/RU2013118325A/ru not_active Application Discontinuation
- 2011-09-22 US US13/825,655 patent/US10143747B2/en not_active Expired - Fee Related
- 2011-09-22 NZ NZ608207A patent/NZ608207A/en not_active IP Right Cessation
- 2011-09-22 AU AU2011306917A patent/AU2011306917B2/en not_active Ceased
- 2011-09-22 CA CA2811556A patent/CA2811556A1/en not_active Abandoned
- 2011-09-22 WO PCT/EP2011/066511 patent/WO2012038504A2/en not_active Ceased
- 2011-09-22 JP JP2013529652A patent/JP6133778B2/ja not_active Expired - Fee Related
-
2013
- 2013-03-21 IL IL225442A patent/IL225442A0/en unknown
- 2013-03-22 CL CL2013000801A patent/CL2013000801A1/es unknown
-
2016
- 2016-10-28 JP JP2016212111A patent/JP2017039771A/ja active Pending
-
2018
- 2018-10-12 US US16/158,504 patent/US20190030161A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013542190A5 (enExample) | ||
| RU2013118325A (ru) | Лечение рака молочной железы | |
| PH12019500845A1 (en) | Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| BR112015029056A2 (pt) | composto, e pílula farmacêutica ou pastilha implantável por via subcutânea para tratar um ser humano que sofre de endometriose | |
| MX2019003685A (es) | Composicion farmaceutica para uso en el tratamiento terapeutico del cancer y complicaciones del cancer. | |
| JP2019530706A5 (enExample) | ||
| MX2022011372A (es) | Composiciones de zinc-y-pga y metodos para tratar el cancer. | |
| NZ630494A (en) | Administration of lorcaserin to individuals with renal impairment | |
| MX2022006566A (es) | Tratamientos conjuntos para tratamiento de cancer de mama. | |
| JP2012525358A5 (enExample) | ||
| JP2019535830A5 (enExample) | ||
| CN110545803A (zh) | 用于淋巴结阳性、早期、激素受体阳性、人表皮生长因子受体2阴性乳腺癌的辅助治疗的内分泌疗法和abemaciclib组合 | |
| Isoda et al. | Repeated rituximab-induced serum sickness with anaphylaxis | |
| SG10201708886RA (en) | α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER | |
| JP2015520763A5 (enExample) | ||
| Bello et al. | Giant conjunctival squamous cell carcinoma. Treatment with surgery following topical interferon alpha-2b | |
| Roeca et al. | Menopause as a Manifestation of Aging | |
| Ah-See | Time to revisit ‘Megace’for hot flushes in patients with breast cancer? | |
| Méndez et al. | Treatment of conjunctival melanoma | |
| Althaqfi et al. | Results of brachytherapy in anal cancer from a cohort of 173 patients treated at the same institution over a 20 year period | |
| ZA202200330B (en) | Pharmaceutical composition of imatinib | |
| Novikova et al. | Hormone therapy alone for pre-cancerous conditions and early endometrial cancer: pros and cons | |
| Aronson et al. | A PHASE 2 OPEN-LABEL TRIAL OF GTX-758 IN MEN WITH CASTRATION-RESISTANT PROSTATE CANCER, FINAL ANALYSIS OF THE PRIMARY ENDPOINT: PD32-03 | |
| NZ791717B2 (en) | Use of pridopidine for treating functional decline |